Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update —BRINSUPRI™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Japan— Exhibit 99.1 —BRINSUPRI Total Revenue of $28.1 Million for the Third Quarter of 2025— —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of$114.3 Million for the Third Quarter of 2025, Reflecting 22% Growth Over the T ...